Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY900014 Formulation in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Overtly healthy male or a female (not pregnant and agreeable to take birth control measures until study completion)~* Have a body mass index (BMI) of 18 to 30 kilogram per square meter (kg/m²), inclusive, at screening~* Have normal blood pressure, pulse rate, electrocardiogram (ECG), blood and urine laboratory test results that are acceptable for the study~* Are nonsmokers, have not smoked for at least 2 months prior to entering the study, and agree not to smoke (cigars, cigarettes, or pipes) or use smokeless tobacco for the duration of the study~Exclusion Criteria:~* Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study~* Have previously participated or withdrawn from this study~* Have or used to have health problems or laboratory test results or ECG readings that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study~* Had blood loss of more than 450 milliliters (mL) within the last month

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- LY900014 (Type: EXPERIMENTAL): Test formulation. 15-U dose of LY900014 administered subcutaneously (SC) in one of two periods.
- Insulin Lispro (Type: ACTIVE_COMPARATOR): Reference formulation. 15-U dose of Insulin Lispro administered SC in one of two periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).